HPMA copolymers for masking and retargeting of therapeutic viruses

被引:60
作者
Fisher, Kerry D. [1 ]
Seymour, Leonard W. [1 ]
机构
[1] Univ Oxford, Dept Clin Pharmacol, Oxford OX3 7DQ, England
关键词
Virus; Viral therapeutics; Vaccine; Vector; Virotherapy; Polymer; Neutralization; POLYMER-COATED ADENOVIRUS; ONCOLYTIC VIROTHERAPY; CIRCULATION TIME; PHASE-II; VECTORS; CANCER; REPLICATION; VACCINE; CELLS; ANTIBODY;
D O I
10.1016/j.addr.2009.12.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hydrophilic polymers are widely used already for steric stabilisation of bioactive proteins, changing their pharmacokinetics and modifying their interactions with the biological environment. Polymers may also be conjugated to biological surfaces, such as viruses, bacteria and mammalian cells, also to endow steric protection and changed properties. Reactive polymers based on N-[2-hydroxypropyl]methacrylamide have shown particular promise for surface coating of viruses, particularly adenovirus. and here we describe the important observations and innovations arising from this combination of chemical and genetic engineering. Adenovirus is a versatile agent that already finds important experimental applications as a recombinant vaccine, and also for cancer therapy, although its activity in both settings is often limited by a potent antibody-neutralising response in humans that is generally not seen in experimental animals. Coating with HPMA copolymers provides protection against neutralisation by antibodies and complement, and covalent linkage of novel ligands to the surface of the polymer can endow new infectious tropisms, mediated through different receptors, that can expand the potential applications of this versatile technology for a range of settings. (C) 2009 Published by Elsevier B.V.
引用
收藏
页码:240 / 245
页数:6
相关论文
共 47 条
[21]   Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission [J].
Lichtenstein, DL ;
Wold, WS .
CANCER GENE THERAPY, 2004, 11 (12) :819-829
[22]   Adenovirus type 5 interactions with human blood cells may compromise systemic delivery [J].
Lyons, Mark ;
Onion, David ;
Green, Nicky K. ;
Aslan, Kriss ;
Rajaratnam, Ratna ;
Bazan-Peregrino, Miriam ;
Phipps, Sue ;
Hale, Sarah ;
Mautner, Vivien ;
Seymour, Leonard W. ;
Fisher, Kerry D. .
MOLECULAR THERAPY, 2006, 14 (01) :118-128
[23]  
MATSUMURA Y, 1986, CANCER RES, V46, P6387
[24]   HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis [J].
McElrath, M. Juliana ;
De Rosa, Stephen C. ;
Moodie, Zoe ;
Dubey, Sheri ;
Kierstead, Lisa ;
Janes, Holly ;
Defawe, Olivier D. ;
Carter, Donald K. ;
Hural, John ;
Akondy, Rama ;
Buchbinder, Susan P. ;
Robertson, Michael N. ;
Mehrotra, Devan V. ;
Self, Steven G. ;
Corey, Lawrence ;
Shiver, John W. ;
Casimiro, Danilo R. .
LANCET, 2008, 372 (9653) :1894-1905
[25]   Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses [J].
Mok, H ;
Palmer, DJ ;
Ng, P ;
Barry, MA .
MOLECULAR THERAPY, 2005, 11 (01) :66-79
[26]   INFLUENCE OF THE STERIC BARRIER ACTIVITY OF AMPHIPATHIC POLY(ETHYLENEGLYCOL) AND GANGLIOSIDE GM1 ON THE CIRCULATION TIME OF LIPOSOMES AND ON THE TARGET BINDING OF IMMUNOLIPOSOMES INVIVO [J].
MORI, A ;
KLIBANOV, AL ;
TORCHILIN, VP ;
HUANG, L .
FEBS LETTERS, 1991, 284 (02) :263-266
[27]   Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor [J].
Morrison, Joanne ;
Briggs, Simon S. ;
Green, Nicola ;
Fisher, Kerry ;
Subr, Vladimir ;
Ulbrich, Karel ;
Kehoe, Sean ;
Seymour, Leonard W. .
MOLECULAR THERAPY, 2008, 16 (02) :244-251
[28]   Cetuximab Retargeting of Adenovirus via the Epidermal Growth Factor Receptor for Treatment of Intraperitoneal Ovarian Cancer [J].
Morrison, Joanne ;
Briggs, Simon S. ;
Green, Nicola K. ;
Thoma, Clemens ;
Fisher, Kerry D. ;
Kehoe, Sean ;
Seymour, Leonard W. .
HUMAN GENE THERAPY, 2009, 20 (03) :239-251
[29]   Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector [J].
Myhre, S. ;
Henning, P. ;
Granio, O. ;
Tylo, A. S. ;
Nygren, P. A. ;
Olofsson, S. ;
Boulanger, P. ;
Lindholm, L. ;
Hong, S-S .
GENE THERAPY, 2007, 14 (04) :376-381
[30]   Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer [J].
Nemunaitis, J ;
Khuri, F ;
Ganly, I ;
Arseneau, J ;
Posner, M ;
Vokes, E ;
Kuhn, J ;
McCarty, T ;
Landers, S ;
Blackburn, A ;
Romel, L ;
Randlev, B ;
Kaye, S ;
Kirn, D .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :289-298